Viewing Study NCT02306850

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:48 PM
Ignite Modification Date: 2026-04-22 @ 7:18 PM
Study NCT ID: NCT02306850
Status: COMPLETED
Last Update Posted: 2019-06-20
First Post: 2014-12-01
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Sponsor: St. Louis University
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Unresectable Malignant Neoplasm View
None Melanoma View
None Metastatic Melanoma View
None Stage IV Melanoma View
None Stage III Melanoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None immunotherapy View
None PD-1 inhibitor View
None programmed death 1 inhibitor View
None neoadjuvant View
None pembrolizumab View
None MK-3475 View